Additionally, resmetirom (MGL‐3196), a selective agonist of the thyroid hormone receptor β that also belongs to the nuclear receptor superfamily I, shows promise as a potential therapy for NASH patients with liver fibrosis.[51] Elucidating the mechanism governing the regulation of Ces2 expression by CAR may inform novel therapeutic strategies for metabolic disorders characterized by TAG accumulation.[52]. Here, NR1I3 is linked to metabolic dysfunction-associated steatohepatitis.